DELRAY BEACH, Fla., March 16, 2012 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID") (OTCBB:PSID), an emerging growth developer of advanced technologies for diabetes management and sophisticated airborne bio-threat detection systems for America's homeland defense industry, today announced it engaged Trilogy Capital Partners, a financial communications and investor relations consultant.
Trilogy is a New York-based financial communications firm providing strategic communications and investor relations support for dynamic and fast growing companies. Trilogy's mandate is to drive investor awareness in PositiveID as it focuses on the need for products to help manage the rapidly increasing presence of diabetes in countries around world, in addition to the Federal government's need for bio-threat detection systems at high-value locations in cities throughout the U.S. and abroad. Trilogy will aim to generate sustainable market interest in PositiveID, while supporting the company's commitment to revenue growth and ultimately shareholder value.
"We believe the depth of Trilogy's investor and media relationships will be an excellent complement to PositiveID's focus on potentially high-growth medical and bio-threat markets," said William J. Caragol, PositiveID Chairman and CEO. "Together with Trilogy, we will maximize outreach to institutional investors and others in the financial community both domestically and abroad."
"As a pioneer of emerging technologies in the medical and bio-threat detection markets, PositiveID is poised to benefit from the projected rapid expansion of these large markets, including a portion of the estimated $3.1 billion Homeland Defense BioWatch pathogen detection contract in the U.S.," said Darren Minton, President of Trilogy. "We are pleased to have the opportunity to work with Mr. Caragol and his team to continue to bring PositiveID's exciting story to new investors within the global investment community."
PositiveID is implementing various corporate growth initiatives in 2012 and is committed to further establishing itself as a global leader developing emerging technologies at the heart of bio-threat detection and diabetes management. In each of these industries, PositiveID will continue to develop its proprietary technologies through a series of strategic initiatives and partnerships, expand its patent portfolio, and pursue organic growth opportunities and accretive acquisitions wherever possible.
About PositiveID Corporation
PositiveID Corporation is an emerging growth developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.
The PositiveID Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7717
For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Forward-Looking Statements
Statements about PositiveID's future expectations, including the likelihood that PositiveID will benefit from the estimated $3.1 billion Homeland Defense BioWatch pathogen detection contract in the U.S.; continue to develop its proprietary technologies through a series of strategic initiatives and partnerships; expand its patent portfolio; pursue organic growth opportunities and accretive acquisitions wherever possible; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully commercialize M-BAND; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.